Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

An expanded risk prediction model for lung cancer.

Spitz MR, Etzel CJ, Dong Q, Amos CI, Wei Q, Wu X, Hong WK.

Cancer Prev Res (Phila). 2008 Sep;1(4):250-4. doi: 10.1158/1940-6207.CAPR-08-0060.

2.

A risk model for prediction of lung cancer.

Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, Shete S, Etzel CJ.

J Natl Cancer Inst. 2007 May 2;99(9):715-26.

PMID:
17470739
3.

Development and validation of a lung cancer risk prediction model for African-Americans.

Etzel CJ, Kachroo S, Liu M, D'Amelio A, Dong Q, Cote ML, Wenzlaff AS, Hong WK, Greisinger AJ, Schwartz AG, Spitz MR.

Cancer Prev Res (Phila). 2008 Sep;1(4):255-65. doi: 10.1158/1940-6207.CAPR-08-0082.

4.

Mutagen sensitivity as a biological marker of lung cancer risk in African Americans.

Spitz MR, Hsu TC, Wu X, Fueger JJ, Amos CI, Roth JA.

Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):99-103.

5.

Incorporation of a genetic factor into an epidemiologic model for prediction of individual risk of lung cancer: the Liverpool Lung Project.

Raji OY, Agbaje OF, Duffy SW, Cassidy A, Field JK.

Cancer Prev Res (Phila). 2010 May;3(5):664-9. doi: 10.1158/1940-6207.CAPR-09-0141. Epub 2010 Apr 27.

6.

Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer.

Rajaee-Behbahani N, Schmezer P, Risch A, Rittgen W, Kayser KW, Dienemann H, Schulz V, Drings P, Thiel S, Bartsch H.

Int J Cancer. 2001 Mar 20;95(2):86-91.

7.

Deletion in poly(ADP-ribose)polymerase pseudogene and lung cancer risk.

Wu X, Hsu TC, Cao S, Lee JJ, Amos CI, Spitz MR.

Carcinogenesis. 1998 Jan;19(1):93-8.

PMID:
9472699
8.

Prospective analysis of DNA damage and repair markers of lung cancer risk from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Sigurdson AJ, Jones IM, Wei Q, Wu X, Spitz MR, Stram DA, Gross MD, Huang WY, Wang LE, Gu J, Thomas CB, Reding DJ, Hayes RB, Caporaso NE.

Carcinogenesis. 2011 Jan;32(1):69-73. doi: 10.1093/carcin/bgq204. Epub 2010 Oct 7.

9.

Lung cancer, smoking patterns, and mutagen sensitivity in Mexican-Americans.

Strom SS, Wu S, Sigurdson AJ, Hsu TC, Fueger JJ, Lopez J, Tee PG, Spitz MR.

J Natl Cancer Inst Monogr. 1995;(18):29-33.

PMID:
8562219
10.
11.

Smoking, DNA repair capacity and risk of nonsmall cell lung cancer.

Shen H, Spitz MR, Qiao Y, Guo Z, Wang LE, Bosken CH, Amos CI, Wei Q.

Int J Cancer. 2003 Oct 20;107(1):84-8.

12.

A risk model for lung cancer incidence.

Hoggart C, Brennan P, Tjonneland A, Vogel U, Overvad K, Østergaard JN, Kaaks R, Canzian F, Boeing H, Steffen A, Trichopoulou A, Bamia C, Trichopoulos D, Johansson M, Palli D, Krogh V, Tumino R, Sacerdote C, Panico S, Boshuizen H, Bueno-de-Mesquita HB, Peeters PH, Lund E, Gram IT, Braaten T, Rodríguez L, Agudo A, Sánchez-Cantalejo E, Arriola L, Chirlaque MD, Barricarte A, Rasmuson T, Khaw KT, Wareham N, Allen NE, Riboli E, Vineis P.

Cancer Prev Res (Phila). 2012 Jun;5(6):834-46. doi: 10.1158/1940-6207.CAPR-11-0237. Epub 2012 Apr 11.

13.

C-reactive protein and risk of lung cancer.

Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR, Chanock SJ, Goedert JJ, Engels EA.

J Clin Oncol. 2010 Jun 1;28(16):2719-26. doi: 10.1200/JCO.2009.27.0454. Epub 2010 Apr 26.

14.

Analysis of aromatic DNA adducts and 7,8-dihydro-8-oxo- 2'-deoxyguanosine in lymphocyte DNA from a case-control study of lung cancer involving minority populations.

Vulimiri SV, Wu X, Baer-Dubowska W, de Andrade M, Detry M, Spitz MR, DiGiovanni J.

Mol Carcinog. 2000 Jan;27(1):34-46. Erratum in: Mol Carcinog 2000 Apr;27(4):330.

PMID:
10642435
15.

[Validity of chromosome analysis and bleomycin sensitivity assay in the prevention of head and neck cancer in Hungary].

Székely G, Remenár E, Kásler M, Bodrog A, Gundy S.

Orv Hetil. 2001 Mar 25;142(12):611-6. Hungarian.

PMID:
11324219
16.

Mutagen sensitivity as a marker of cancer susceptibility.

Spitz MR, Wu X, Jiang H, Hsu TC.

J Cell Biochem Suppl. 1996;25:80-4.

PMID:
9027602
17.

Interplay between mutagen sensitivity and epidemiological factors in modulatinglung cancer risk.

Wu X, Lin J, Etzel CJ, Dong Q, Gorlova OY, Zhang Q, Amos CI, Spitz MR.

Int J Cancer. 2007 Jun 15;120(12):2687-95.

18.

The cytokinesis-blocked micronucleus assay as a strong predictor of lung cancer: extension of a lung cancer risk prediction model.

El-Zein RA, Lopez MS, D'Amelio AM Jr, Liu M, Munden RF, Christiani D, Su L, Tejera-Alveraz P, Zhai R, Spitz MR, Etzel CJ.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2462-70. doi: 10.1158/1055-9965.EPI-14-0462. Epub 2014 Aug 29.

19.

Rapid method for determination of DNA repair capacity in human peripheral blood lymphocytes amongst smokers.

El-Zein RA, Monroy CM, Cortes A, Spitz MR, Greisinger A, Etzel CJ.

BMC Cancer. 2010 Aug 18;10:439. doi: 10.1186/1471-2407-10-439.

20.

Hormone replacement therapy and lung cancer risk: a case-control analysis.

Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):113-23.

Supplemental Content

Support Center